文献速递头颈部肿瘤放疗

早期口咽癌低体积颈部病变:放化疗与单纯放疗的队列研究

Chemoradiation Therapy Versus Radiation Therapy Alone in T1-2 Oropharyngeal Cancer With Low-Volume Neck Disease: A Population-Based Cohort Study Using the Swedish Head and Neck Cancer Register.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-08-21

基于瑞典头颈癌登记的前瞻性队列研究,纳入1507例T1-2N1-2b口咽鳞癌患者,经倾向性评分匹配后比较放化疗与单纯放疗。

要点

  • T1-2N1-2a口咽鳞癌单纯放疗与放化疗总生存和局部区域控制均无显著差异。
  • T1-2N2b且≤70岁患者放化疗改善局部区域控制,但总生存未获益。
  • T1-2N2b且>70岁患者放化疗无局部区域控制获益。

核心结论

  • T1-2N1-2a口咽鳞癌单纯放疗是安全选择。
  • T1-2N2b且≤70岁患者放化疗改善局部区域控制但不改善总生存。

研究设计与样本

  • 基于瑞典头颈癌登记的前瞻性队列研究,利用医疗区域间放化疗使用差异。
  • 采用1:1倾向性评分匹配平衡基线特征。
  • 分别对T1-2N1-2a队列和T1-2N2b队列进行匹配和分析。
  • 共纳入1507例T1-2N1-2b口咽鳞癌患者,匹配后N1-2a队列262例,N2b队列692例。

主要发现

  • N1-2a队列局部区域控制放化疗与单纯放疗相似(HR 0.98,95%CI 0.34-2.78,p=0.98)。
  • 局部区域控制差异由原发灶失败驱动,探索性分析提示T2N2b患者可能选择性获益于放化疗。

关键数值与推荐

  • N1-2a定义为单个淋巴结<6 cm,N2b定义为多个淋巴结<6 cm(UICC第7版)。
  • N1-2a队列局部区域控制HR 0.98(95%CI 0.34-2.78,p=0.98)。

临床怎么用

  • T1-2N1-2a口咽鳞癌可考虑单纯放疗,避免不必要的化疗毒性。
  • T1-2N2b且≤70岁患者可考虑放化疗以改善局部区域控制,但需权衡总生存无获益。
  • T1-2N2b且>70岁患者放化疗无局部区域控制获益,倾向单纯放疗。
  • T2N2b患者可能从放化疗中选择性获益,需个体化决策。

局限性

  • 为基于登记数据的观察性队列研究,存在未测量混杂可能。
  • 放化疗暴露基于医疗区域差异,非随机分配。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The benefit of adding concurrent systemic therapy to definitive radiation therapy (RT) for patients with T1-2 oropharyngeal squamous cell carcinoma (OPSCC) and limited neck node involvement is uncertain. This study investigates whether chemotherapy (CRT) in patients with early-stage (T1-2) low-volume nodal disease (Union for International Cancer Control Seventh Edition N1-2b) improves overall survival (OS) compared with RT alone. METHODS AND MATERIALS: A cohort study of data from the prospective Swedish Head and Neck Cancer Register leveraged variation in receiving CRT based on the health care region. Propensity score matching (1:1) was applied to balance baseline characteristics between patients from regions favoring CRT and those receiving RT alone. OS and loco-regional control (LRC) were compared between groups using Kaplan-Meier analyses and Cox regression models. Separate matching and analyses were conducted for patients with T1-2N1-2a (cohort N1-2a, ie, single node < 6 cm) and T1-2N2b disease (cohort N2b, ie, multiple nodes < 6 cm). RESULTS: A total of 1507 patients with T1-2N1-2b OPSCC were included. After propensity score matching, cohort N1-2a consisted of 262 patients and cohort N2b of 692 patients. OS was similar between CRT and RT alone in both cohorts, with a hazard ratio (HR) of 1.57 (95% CI, 0.68-3.87; p = .17) for cohort N1-2a, and an HR of 0.95 (95% CI, 0.66-1.35; p = .77) for cohort N2b. LRC was also similar between CRT and RT in cohort N1-2a (HR, 0.98 [95% CI, 0.34-2.78]; p = .98). In cohort N2b, a statistical interaction (p < .001) was found with age, with a benefit of CRT for patients aged ≤70 years (HR, 0.30 [95% CI, 0.16-0.58]), but not for patients aged >70 years (HR, 1.48 [95% CI, 0.50-4.39]). The difference in LRC was driven by failures at the primary tumor site. Exploratory analyses suggested a selective benefit of CRT for patients with T2N2b. CONCLUSIONS: The results of this large, robust, national register suggest that RT alone is a safe treatment option for patients with T1-2N1-2a OPSCC. In patients with multiple neck nodes (N2b) aged ≤70 years, CRT improved LRC but not overall survival.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Adrian G, Falklind NR, McDowell L, et al. Chemoradiation Therapy Versus Radiation Therapy Alone in T1-2 Oropharyngeal Cancer With Low-Volume Neck Disease: A Population-Based Cohort Study Using the Swedish Head and Neck Cancer Register. Int J Radiat Oncol Biol Phys. 2025. PMID: 40848943. doi:10.1016/j.ijrobp.2025.08.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。